CN109172363A - 静脉内施用格列苯脲和其他药物的方法 - Google Patents

静脉内施用格列苯脲和其他药物的方法 Download PDF

Info

Publication number
CN109172363A
CN109172363A CN201810945946.3A CN201810945946A CN109172363A CN 109172363 A CN109172363 A CN 109172363A CN 201810945946 A CN201810945946 A CN 201810945946A CN 109172363 A CN109172363 A CN 109172363A
Authority
CN
China
Prior art keywords
glibenclamide
glyburide
drug
drugs
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810945946.3A
Other languages
English (en)
Chinese (zh)
Inventor
S·M·雅各布森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pizza Co
Original Assignee
Pizza Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pizza Co filed Critical Pizza Co
Publication of CN109172363A publication Critical patent/CN109172363A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Anesthesiology (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medicinal Preparation (AREA)
CN201810945946.3A 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法 Pending CN109172363A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36568910P 2010-07-19 2010-07-19
US61/365,689 2010-07-19
CN201180044843.6A CN103108637B (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201180044843.6A Division CN103108637B (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Publications (1)

Publication Number Publication Date
CN109172363A true CN109172363A (zh) 2019-01-11

Family

ID=45497399

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810945946.3A Pending CN109172363A (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法
CN201180044843.6A Active CN103108637B (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201180044843.6A Active CN103108637B (zh) 2010-07-19 2011-07-18 静脉内施用格列苯脲和其他药物的方法

Country Status (7)

Country Link
US (9) US8946293B2 (https=)
EP (3) EP3339190A1 (https=)
JP (5) JP6188021B2 (https=)
KR (8) KR20250026419A (https=)
CN (2) CN109172363A (https=)
CA (3) CA3225438A1 (https=)
WO (1) WO2012012347A2 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010247800A1 (en) 2009-05-11 2011-12-15 Berg Llc Methods for the diagnosis of metabolic disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
EP3339190A1 (en) 2010-07-19 2018-06-27 Biogen Chesapeake LLC Containers for glyburide solutions
HUE045889T2 (hu) * 2010-10-21 2020-01-28 Rtu Pharmaceuticals Llc Használatkész ketorolak készítmények
CA2832324C (en) 2011-04-04 2022-03-15 Berg Llc Methods of treating central nervous system tumors
JP6238969B2 (ja) 2012-05-08 2017-11-29 エアロミクス・インコーポレイテッドＡｅｒｏｍｉｃｓ，Ｉｎｃ． 新規方法
SG10201903112WA (en) 2013-04-08 2019-05-30 Berg Llc Treatment of cancer using coenzyme q10 combination therapies
KR102370843B1 (ko) * 2013-09-04 2022-03-04 버그 엘엘씨 코엔자임 q10의 연속주입에 의한 암치료 방법
WO2015069956A2 (en) 2013-11-06 2015-05-14 Aeromics, Llc Novel formulations
MX384247B (es) 2015-05-29 2025-03-14 Univ Maryland Antagonistas del sur1- trpm4 para usarse para reducir o prevenir daño a la íntima provocado por estimulación mecánica de células endoteliales.
CA3001321A1 (en) * 2015-10-07 2017-04-13 Biogen Chesapeake Llc Methods of treating injuries or conditions related to cns edema
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
JP7165648B2 (ja) 2016-07-29 2022-11-04 バイオジェン チェサピーク エルエルシー Ｓｕｒ１－ｔｒｐｍ４チャネル阻害剤による医療処置方法
WO2018204721A1 (en) 2017-05-05 2018-11-08 Nino Sorgente Methods and compositions for improving eye health
US11382881B2 (en) 2017-05-05 2022-07-12 Nino Sorgente Methods and compositions for diagnosing and treating glaucoma
CN108078999B (zh) * 2017-12-22 2020-08-14 沈阳药科大学 用于防治缺血性脑卒中的药物组合物及其制备方法和用途
CN120004770A (zh) 2020-07-17 2025-05-16 上海森辉医药有限公司 磺酰脲类衍生物及其医药用途
US12251389B1 (en) 2024-04-22 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema
US12251388B1 (en) 2024-05-09 2025-03-18 Remedy Pharmaceuticals, Inc. Methods of treating ischemic stroke at risk for cerebral or cerebellar edema

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1759043A (zh) * 2003-01-09 2006-04-12 巴克斯特健康护理股份有限公司 用于生物活性物质的安全容器及其制造方法
CN1960735A (zh) * 2004-05-20 2007-05-09 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用
CN101043891A (zh) * 2004-09-18 2007-09-26 巴尔的摩马里兰大学 靶向NCCa－ATP通道的治疗剂及其使用方法
CN101229316A (zh) * 2008-01-31 2008-07-30 广东药学院 一种知母提取物及其作为治疗2型糖尿病药物的应用
WO2009002832A2 (en) * 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856360A (en) * 1996-05-03 1999-01-05 Children's Hospital Medical Center Pharmaceutical method for the treatment of severe blood loss and for the inhibition or treatment of hemorrhagic shock
US20080220441A1 (en) 2001-05-16 2008-09-11 Birnbaum Eva R Advanced drug development and manufacturing
EP2438913B1 (en) 2002-03-20 2020-05-06 University of Maryland, Baltimore A non-selective cation channel in neural cells and compounds that block the channel for use in treating brain swelling
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US20040073192A1 (en) * 2002-10-15 2004-04-15 Flament-Garcia Mary Jane Intravenous fluid delivery set
US20050148928A1 (en) * 2003-12-31 2005-07-07 Medtronic Minimed, Inc. Multiple layer tubing and method of making same
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
AU2005322136B2 (en) * 2004-12-23 2011-01-06 Hospira, Inc. Port closure system for intravenous fluid container
HRP20130150T1 (hr) * 2006-09-29 2013-03-31 Infa S.A. Sustav pakiranja farmaceutskih sastava i komplet za intravenozno davanje
US20110034560A1 (en) * 2008-01-29 2011-02-10 Sven Jacobson Liquid formulations of compounds active at sulfonylurea receptors
EP3339190A1 (en) 2010-07-19 2018-06-27 Biogen Chesapeake LLC Containers for glyburide solutions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1759043A (zh) * 2003-01-09 2006-04-12 巴克斯特健康护理股份有限公司 用于生物活性物质的安全容器及其制造方法
CN1960735A (zh) * 2004-05-20 2007-05-09 代阿麦迪卡股份有限公司 药物组合在治疗胰岛素抗性中的应用
CN101043891A (zh) * 2004-09-18 2007-09-26 巴尔的摩马里兰大学 靶向NCCa－ATP通道的治疗剂及其使用方法
WO2009002832A2 (en) * 2007-06-22 2008-12-31 University Of Maryland, Baltimore Inhibitors of ncca-atp channels for therapy
CN101229316A (zh) * 2008-01-31 2008-07-30 广东药学院 一种知母提取物及其作为治疗2型糖尿病药物的应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
C. DE MUYNCK等: "BINDXNG OF DRUGS TO END-LINE FILTERS: A STUDY OF", 《JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS》 *
JOHN G. PEARSON, PH.D.: "Pharmacokinetics of Glyburide", 《THE AMERICAN JOURNAL OF MEDICINE》 *
M. GERARD LEE: "Sorption of four drugs to polyvinyrchloride and polybutadiene intravenous administration sets", 《AMERICAN JOURNAL OF HOSPITAL PHARMACY》 *

Also Published As

Publication number Publication date
KR20220000943A (ko) 2022-01-04
KR101917975B1 (ko) 2018-11-13
EP3586850A1 (en) 2020-01-01
JP6506335B2 (ja) 2019-04-24
US10391053B2 (en) 2019-08-27
KR20200054319A (ko) 2020-05-19
CA2806069A1 (en) 2012-01-26
US20150157560A1 (en) 2015-06-11
JP2013532658A (ja) 2013-08-19
US9254259B2 (en) 2016-02-09
CA2806069C (en) 2021-01-19
KR20130133165A (ko) 2013-12-06
KR20250026419A (ko) 2025-02-25
US10052280B2 (en) 2018-08-21
CA3225438A1 (en) 2012-01-26
US9561176B2 (en) 2017-02-07
KR20170118960A (ko) 2017-10-25
JP6188021B2 (ja) 2017-08-30
US10786445B2 (en) 2020-09-29
KR20230165363A (ko) 2023-12-05
US20130203853A1 (en) 2013-08-08
CA3101711C (en) 2024-02-13
CN103108637B (zh) 2018-09-14
CN103108637A (zh) 2013-05-15
US20210154135A1 (en) 2021-05-27
EP2595633A4 (en) 2014-01-22
US20250221924A1 (en) 2025-07-10
US20160030370A1 (en) 2016-02-04
JP2017105846A (ja) 2017-06-15
US12226521B2 (en) 2025-02-18
KR20180123176A (ko) 2018-11-14
AU2011279878A1 (en) 2013-03-07
JP2019038855A (ja) 2019-03-14
US11559481B2 (en) 2023-01-24
JP6179574B2 (ja) 2017-08-16
WO2012012347A2 (en) 2012-01-26
EP3339190A1 (en) 2018-06-27
US20170333340A1 (en) 2017-11-23
EP2595633A2 (en) 2013-05-29
CA3101711A1 (en) 2012-01-26
WO2012012347A3 (en) 2012-05-10
JP2020073595A (ja) 2020-05-14
US20230414489A1 (en) 2023-12-28
KR20190031592A (ko) 2019-03-26
JP6795571B2 (ja) 2020-12-02
US20170348227A1 (en) 2017-12-07
US20190328653A1 (en) 2019-10-31
US8946293B2 (en) 2015-02-03
JP2016020393A (ja) 2016-02-04

Similar Documents

Publication Publication Date Title
CN109172363A (zh) 静脉内施用格列苯脲和其他药物的方法
US10758503B2 (en) Composition containing glibenclamide
HK40002343A (en) Methods of intravenous administration of glyburide and other drugs
Class et al. Patent application title: METHODS OF INTRAVENOUS ADMINISTRATION OF GLYBURIDE
HK40020325A (en) Methods of intravenous administration of glyburide and other drugs
HK1185276B (en) Methods of intravenous administration of glyburide and other drugs
HK1185276A (en) Methods of intravenous administration of glyburide and other drugs

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40002343

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190111

WD01 Invention patent application deemed withdrawn after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 40002343

Country of ref document: HK